Anatomy and Cell Biology

  • 제56권1호
  • /
  • Pages.109-121
  • /
  • 2023
  • /
  • 2093-3665(pISSN)
  • /
  • 2093-3673(eISSN)
대한해부학회 (Korean Association of Anatomists)
권호 표지
DOI QR코드

DOI QR Code

The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats

  • Ahmed H. Moustafa (Department of Chemistry, Faculty of Science, Zagazig University) ;
  • Heba F. Pasha (Department of Medical Biochemistry and Genetics, Faculty of Medicine, Zagazig University) ;
  • Manar A. Abas (Department of Biochemistry, Faculty of Science, Zagazig University) ;
  • Adel M. Aboregela (Department of Human Anatomy and Embryology, Faculty of Medicine, Zagazig University)
  • 투고 : 2022.10.10
  • 심사 : 2022.11.21
  • 발행 : 2023.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Thioacetamide (TAA) exposure and hepatitis C virus infection are usually associated with renal dysfunction. Sofosbuvir (SFV) and daclatasvir (DAC) drugs combination has great value in the treatment of hepatitis C. The study aimed to identify the nephrotoxic effects of TAA and to evaluate the ameliorative role of SFV and DAC in this condition. Forty-eight adult male albino rats were divided into eight groups and received saline (control), SFV, DAC, SFV+DAC, TAA, TAA+SFV, TAA+DAC and TAA+SFV+DAC for eight weeks. Kidney and blood samples were retrieved and processed for histological (Hematoxylin and Eosin and Masson's trichrome), immunohistochemical (α-smooth muscle actin), and biochemical analysis (urea, creatinine, total protein, albumin, malondialdehyde, reduced glutathione, superoxide dismutase, and tumor necrosis factor-α). Examination revealed marked destruction of renal tubules on exposure to TAA with either hypertrophy or atrophy of glomeruli, increase in collagen deposition, and wide expression of α-smooth muscle actin. Also, significant disturbance in kidney functions, oxidative stress markers, and tumor necrosis factor-α. Supplementation with either SFV or DAC produced mild improvement in the tissue and laboratory markers. Moreover, the combination of both drugs greatly refined the pathology induced by TAA at the cellular and laboratory levels. However, there are still significant differences when compared to the control. In conclusion, SFV and DAC combination partially but greatly ameliorated the renal damage induced by TAA which might be enhanced with further supplementations to give new hope for those with nephropathy associated with hepatitis.

키워드

과제정보

The authors would like to thank the administration team for helping to overcome difficulties. In addition, the efforts carried out by the team of ZSMRC for supporting experimentation in their laboratories were highly appreciated. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

참고문헌

  1. Alamery S, Zargar S, Yaseen F, Wani TA, Siyal A. Evaluation of the effect of wheat germ oil and olmutinib on the thioacetamide-induced liver and kidney toxicity in mice. Life (Basel) 2022;12:900.
  2. Zargar S, Alonazi M, Rizwana H, Wani TA. Resveratrol reverses thioacetamide-induced renal assault with respect to oxidative stress, renal function, DNA damage, and cytokine release in Wistar rats. Oxid Med Cell Longev 2019;2019:1702959.
  3. Ghosh S, Sarkar A, Bhattacharyya S, Sil PC. Silymarin protects mouse liver and kidney from thioacetamide induced toxicity by scavenging reactive oxygen species and activating PI3K-Akt pathway. Front Pharmacol 2016;7:481.
  4. Kadir FA, Othman F, Abdulla MA, Hussan F, Hassandarvish P. Effect of Tinospora crispa on thioacetamide-induced liver cirrhosis in rats. Indian J Pharmacol 2011;43:64-8.
  5. Vokalova L, Laukova L, Conka J, Meliskova V, Borbelyova V, Babickova J, Tothova L, Hodosy J, Vlkova B, Celec P. Deoxyribonuclease partially ameliorates thioacetamide-induced hepatorenal injury. Am J Physiol Gastrointest Liver Physiol 2017;312:G457-63.
  6. Al-Attar AM, Alrobai AA, Almalki DA. Protective effect of olive and juniper leaves extracts on nephrotoxicity induced by thioacetamide in male mice. Saudi J Biol Sci 2017;24:15-22.
  7. Hajovsky H, Hu G, Koen Y, Sarma D, Cui W, Moore DS, Staudinger JL, Hanzlik RP. Metabolism and toxicity of thioacetamide and thioacetamide S-oxide in rat hepatocytes. Chem Res Toxicol 2012;25:1955-63.
  8. Ozbek E. Induction of oxidative stress in kidney. Int J Nephrol 2012;2012:465897.
  9. Schyman P, Printz RL, Estes SK, Boyd KL, Shiota M, Wallqvist A. Identification of the toxicity pathways associated with thioacetamide-induced injuries in rat liver and kidney. Front Pharmacol 2018;9:1272.
  10. Mansour RSAE, Ezzat SF, Abou-Bakr DA. Ameliorative effect of propolis against thioacetamide induced hepatorenal injury in adult male rats. Kidney injury molecule-1 (KIM-1) a biomarker of renal injury. Med J Cairo Univ 2020;88:243-58.
  11. Lam HYP, Hung MY, Liang TR, Peng SY. An in-vivo study into the effects of schisandrin B in the liver, spleen, kidney, and brain of acute thioacetamide-intoxicated mice. Iran J Pharm Res 2021;20:300-14.
  12. Turkmen NB, Yuce H, Taslidere A, Sahin Y, Ciftci O. The ameliorate effects of nerolidol on thioacetamide-induced oxidative damage in heart and kidney tissue. Turk J Pharm Sci 2022;19:1-8.
  13. Soderholm J, Millbourn C, Busch K, Kovamees J, Schvarcz R, Lindahl K, Bruchfeld A. Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis. J Hepatol 2018;68:904-11.
  14. Poustchi H, Majd Jabbari S, Merat S, Sharifi AH, Shayesteh AA, Shayesteh E, Minakari M, Fattahi MR, Moini M, Roozbeh F, Mansour-Ghanaei F, Afshar B, Mokhtare M, Amiriani T, Sofian M, Somi MH, Agah S, Maleki I, Latifnia M, Fattahi Abdizadeh M, Hormati A, Khoshnia M, Sohrabi M, Malekzadeh Z, Merat D, Malekzadeh R. The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. J Gastroenterol Hepatol 2020;35:1590-4.
  15. Eletreby R, Elakel W, Said M, El Kassas M, Seif S, Elbaz T, El Raziky M, Abdel Rehim S, Zaky S, Fouad R, Gamal Eldeen H, Abdo M, Korany M, Yosry A, El Serafy M, El-Sayed MH, ElShazly Y, Waked I, Doss W, Esmat G. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int 2017;37:534-41.
  16. Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS, Geiss BJ. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res 2017;137:134-40.
  17. Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA. Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β- C-methyluridine) as an inhibitor of Dengue virus replication. Sci Rep 2017;7:6345.
  18. Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015;42:258-72.
  19. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21. Erratum in: N Engl J Med 2014;370:1469.
  20. McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. Drugs 2015;75:515-24.
  21. Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd- Elsalam S. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist 2018;11:441-5.
  22. Yakoot M, El-Shabrawi MH, AbdElgawad MM, Mahfouz AA, Helmy S, Abdo AM, El-Khayat HR. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018;67:86-9.
  23. Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, Abbaspour Kasgari H, Tirgar Fakheri H, Merat S, Hill A. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother 2021;76:286-91. Erratum in: J Antimicrob Chemother 2021;76:1653.
  24. Hamed M, El-Hasab M, Mansour FR. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors. Virusdisease 2021;32:279-85.
  25. Zein AFMZ, Sulistiyana CS, Raffaello WM, Wibowo A, Pranata R. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J 2022;98:509-14.
  26. Rezk MM, Ali HA, Moustafa AH, Ali EM. Study the biochemical activities of anti-HCV drugs on thioacetamide induced hepatic fibrosis. J Pharm Appl Chem 2018;4:189-200.
  27. Li X, Peng T. Strategy, progress, and challenges of drug repurposing for efficient antiviral discovery. Front Pharmacol 2021;12:660710.
  28. Shin JW, Seol IC, Son CG. Interpretation of animal dose and human equivalent dose for drug development. J Korean Orient Med 2010;31:1-7.
  29. Bancroft JD, Gamble M. Theory and practice of histological techniques. 6th ed. Philadelphia: Churchill Livingstone/Elsevier; 2008.
  30. Shalaby AM, Ibrahim MAAH, Aboregela AM. Effect of aspartame on the placenta of adult albino rat. A histological and immunohistochemical study. Ann Anat 2019;224:133-41.
  31. Shalaby AM, Aboregela AM, Alabiad MA, El Shaer DF. Tramadol promotes oxidative stress, fibrosis, apoptosis, ultrastructural and biochemical alterations in the adrenal cortex of adult male rat with possible reversibility after withdrawal. Microsc Microanal 2020;26:509-23.
  32. Tietz NW, Andresen BD. Textbook of clinical chemistry. Philadelphia: W.B. Saunders; 1986.
  33. Young DS, Bermes EW. Specimen collection and processing: sources of biological variation. In: Tietz NW, Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia: Saunders; 1994. p.58-102.
  34. Ruot B, Breuille D, Rambourdin F, Bayle G, Capitan P, Obled C. Synthesis rate of plasma albumin is a good indicator of liver albumin synthesis in sepsis. Am J Physiol Endocrinol Metab 2000;279:E244-51.
  35. Aboregela A, Ibrahim A, Raafat N, Sabbah N. Possible ameliorating role of ascorbic acid on intestinal changes induced by acrylamide in adult female albino rats and their offsprings. Egypt J Histol 2020;43:1115-27.
  36. Tawfeek SE, Domouky AM, Abdel-Kareem RH. Protective effect of vitamin C against ivermectin induced nephrotoxicity in different age groups of male wistar rats: bio-histopathological study. Anat Cell Biol 2021;54:501-17.
  37. Aziziaram Z, Bilal I, Zhong Y, Mahmod AK, Roshandel MR. Protective effects of curcumin against naproxen-induced mitochondrial dysfunction in rat kidney tissue. Cell Mol Biomed Rep 2021;1:23-32.
  38. Raj D, Tomar B, Lahiri A, Mulay SR. The gut-liver-kidney axis: novel regulator of fatty liver associated chronic kidney disease. Pharmacol Res 2020;152:104617.
  39. Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, Czubkowski P, Gupte G, Mozer-Glassberg Y, van der Woerd W, Smets F, Verkade HJ, Fischler B. Treatment of chronic hepatitis C virus infection in children: a position paper by the hepatology committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:505-15.
  40. Marques PE, Oliveira AG, Pereira RV, David BA, Gomides LF, Saraiva AM, Pires DA, Novaes JT, Patricio DO, Cisalpino D, Menezes-Garcia Z, Leevy WM, Chapman SE, Mahecha G, Marques RE, Guabiraba R, Martins VP, Souza DG, Mansur DS, Teixeira MM, Leite MF, Menezes GB. Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice. Hepatology 2015;61:348-60.
  41. Lim JY, Jung WW, Kim W, Moon KS, Sul D. Nephrotoxicity evaluation and proteomic analysis in kidneys of rats exposed to thioacetamide. Sci Rep 2022;12:6837.
  42. Keshk WA, Zahran SM. Mechanistic role of cAMP and hepatocyte growth factor signaling in thioacetamide-induced nephrotoxicity: unraveling the role of platelet rich plasma. Biomed Pharmacother 2019;109:1078-84.
  43. Bashandy SAE, El Awdan SA, Mohamed SM, Omara EAA. Allium porrum and Bauhinia Variegata mitigate acute liver failure and nephrotoxicity induced by thioacetamide in male rats. Indian J Clin Biochem 2020;35:147-57.
  44. Celik H, Camtosun A, Ciftci O, Cetin A, Aydin M, Gurbuz S. Beneficial effects of nerolidol on thioacetamide-induced damage of the reproductive system in male rats. Biomed Res 2016;27:725-30.
  45. Wang ME, Chen YC, Chen IS, Hsieh SC, Chen SS, Chiu CH. Curcumin protects against thioacetamide-induced hepatic fibrosis by attenuating the inflammatory response and inducing apoptosis of damaged hepatocytes. J Nutr Biochem 2012;23:1352-66.
  46. Kadir FA, Kassim NM, Abdulla MA, Yehye WA. Effect of oral administration of ethanolic extract of Vitex negundo on thioacetamide- induced nephrotoxicity in rats. BMC Complement Altern Med 2013;13:294.
  47. Osman A, El-Hadary A, Korish AA, AlNafea HM, Alhakbany MA, Awad AA, Abdel-Hamid M. Angiotensin-I converting enzyme inhibition and antioxidant activity of papain-hydrolyzed camel whey protein and its hepato-renal protective effects in thioacetamide-induced toxicity. Foods 2021;10:468.
  48. Saad HM, Oda SS, Sedeek EK. Protective effect of Lacteol® forte against thioacetamide-induced hepatic injury in male albino rats. Alex J Vet Sci 2020;67:92-8.
  49. Childs K, Merritt E, Considine A, Sanchez-Fueyo A, Agarwal K, Martinez-Llordella M, Carey I. Immunological predictors of nonresponse to directly acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Open Forum Infect Dis 2017;4:ofx067.
  50. Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med 2016;8:21-6.